Lisanti Capital Growth LLC Sells 25,775 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Lisanti Capital Growth LLC lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 48.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,175 shares of the company's stock after selling 25,775 shares during the period. Lisanti Capital Growth LLC owned about 0.08% of TransMedics Group worth $4,266,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue purchased a new position in TransMedics Group in the 3rd quarter valued at approximately $2,560,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company's stock valued at $94,061,000 after purchasing an additional 30,092 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of TransMedics Group during the 2nd quarter worth approximately $1,400,000. Handelsbanken Fonder AB lifted its stake in TransMedics Group by 657.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company's stock valued at $10,111,000 after buying an additional 55,900 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in TransMedics Group by 337,462.5% during the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company's stock valued at $1,997,000 after buying an additional 26,997 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Nicholas Corcoran sold 10,000 shares of the firm's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares of the company's stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company's stock, valued at approximately $3,714,902.10. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is owned by company insiders.

TransMedics Group Trading Up 4.3 %

Shares of NASDAQ:TMDX traded up $3.66 during trading on Monday, hitting $89.64. 1,378,898 shares of the company's stock were exchanged, compared to its average volume of 952,706. The firm has a market cap of $3.01 billion, a P/E ratio of 91.47 and a beta of 2.08. TransMedics Group, Inc. has a 1-year low of $56.83 and a 1-year high of $177.37. The firm has a 50-day moving average price of $132.03 and a two-hundred day moving average price of $139.89. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business earned ($0.12) earnings per share. TransMedics Group's revenue for the quarter was up 63.7% on a year-over-year basis. Equities analysts predict that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Needham & Company LLC dropped their price objective on TransMedics Group from $208.00 to $109.00 and set a "buy" rating for the company in a research report on Tuesday, October 29th. Robert W. Baird lowered their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating for the company in a research report on Tuesday, October 29th. Canaccord Genuity Group dropped their price objective on TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a report on Tuesday, October 29th. Piper Sandler reissued an "overweight" rating and issued a $180.00 target price on shares of TransMedics Group in a research note on Tuesday, October 29th. Finally, Morgan Stanley raised their target price on TransMedics Group from $104.00 to $145.00 and gave the company an "equal weight" rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $144.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.